EXEL logo

EXEL Exelixis, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$68.29
-0.21 (-0.31%)

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treat…

Market Cap: $17.17Bwww.exelixis.com

Price

No data yet.

Social Signal Score

58
5d
64
3 mentions
—
30d
58
18 mentions
—
60d
58
24 mentions
—
90d
54
45 mentions
—
news: 35 · marketaux: 1 · rss: 9

Analyst Ratings

33 analysts
Holdconsensus
Strong Buy 0Buy 15Hold 18Sell 0Strong Sell 0
Avg price target$54.2-20.6%
Low $49Median $52.5High $65
Current Consensus

Revenue

$658.70M+749.04%
$77.58M$271.29M$464.99M$658.70M
Dec 2016Oct 2026

Analyst Estimates

FY2026
$2.98
$2.80–$3.12
11 analysts
FY2027
$3.71+25% YoY
$3.50–$3.88
9 analysts
FY2028
$4.25+14% YoY
$3.49–$5.13
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Michael Morrissey
Sector
Healthcare
Industry
Biotechnology
Employees
1,077
Beta
0.42
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
17.98
www.exelixis.com